产品名称：Stemgent/StainAlive TRA-1-60 Antibody (DyLight 488)/09-0068/100 μl

产品编号：09-0068

市场价：¥0.00

场地：美国(厂家直采)

产品分类：抗体类>一抗>功能性抗体>

联系QQ：1570468124

电话号码：4000-520-616

邮箱： info@ebiomall.com

美元价：待定

品牌： Stemgent

公司：Stemgent, Inc

公司分类：

商品介绍

09-0068_TRA-1-60_Immunocytochemical_H1humanES

ImmunocytochemicalanalysisofTRA-1-60onH1humanEScells.PhasecontrastviewofcellsincultureandthesamefieldofviewafterstainingwithStainAliveTRA-1-60Antibody(DyLight488)usinga1:100dilution.

ProductOverview

TheTRA-1-60antibodyreactswithapluripotent,stemcellspecificantigenexpressedonundifferentiatedhumanembryonicstem(ES)cells,embryonalcarcinoma(EC)cells,andembryonicgerm(EG)cells.TheexpressionofTRA-1-60onhumanEScellsisdown-regulatedupondifferentiation.TheTRA-1-60antibodyrecognizesaneuraminidase-resistantcarbohydrateepitopeexpressedonpodocalyxin,amemberoftheCD34-relatedfamilyofsialomucins.Podocalyxinisatransmembraneglycoprotein,whichhasbeenimplicatedinthedevelopmentofaggressivenessinavarietyofcancers,includingbreastandprostatecancer.

Thisantibodyisidealforlive-stainingcells,becauseithasbeenspecificallyformulatedwithlowendotoxinandnosodiumazide.Thisallowsin-processmonitoringofreprogrammingexperimentswithoutsacrificingcells.EScellmorphology,proliferation,andexpressionofpluripotencyMarkersdoesnotchangeafterstainingwithStainAliveTRA-1-60antibody.

ProductSpecifications

Size

100μl

Concentration

0.5mg/ml

Clone

TRA-1-60

Isotype

MouseIgM,κ

Immunogen

Humanembryonalcarcinoma(EC)cellline2102Ep

Reactivity

Human

Preparation

ThisantibodywaspurifiedbyaffinitychromatographyandconjugatedwithDyLight488underoptimalconditions.Thesolutionisfreeofunconjugateddyeandunlabeledantibody.0.2μmfiltersterilized.Formulationisfreefrombacteria,fungi,mycoplasma,andmousevirus.

Formulation

Phosphate-bufferedsolution,pH7.2,containingnopreservative

StorageandStABIlity

Storeat4°Cprotectedfromlight.Donotfreeze.Handleunderasepticconditions.Stablefor6monthsfromdateofreceiptwhenstoredasdirected.

QualityControl

Testedbyimmunocytochemistrytoensureproductquality.
Endotoxinlevelislessthan0.1EU/μg(0.01ng/μg)oftheproteinasdeterminedbytheLALassay.

RecommendedUsage

Thesuggesteduseofthisantibodyisa1:100dilutionforimmunocytochemistry.Foranapplicationspecificprotocol,pleasereferenceProtocol:ImmunocytochemistryofLiveCellsonlineatwww.Stemgent.com/support/protocols.

SpecificationSheets

09-0068SpecificationsSheet

SafetyDataSheets

09-0068SafetyDataSheet

Protocols

GeneralProtocolforICCStainingofLiveCells

RelatedProducts

mRNAReprogrammingKit(00-0071)
microRNABoosterKit(00-0073)

References

Takahashi,K.,TanabeK.,Ohnuki,M.,Narita,M.,IchisakaT.,TomodaK.andYamanaka,S.(2007)Inductionofpluripotentstemcellsfromadulthumanfibroblastsbydefinedfactors.Cell131:861-872.
Yu,J.,Vodyanik,M.A.,Smuga-Otto,K.,Antosiewicz-Bourget,J.,Frane,J.L.,Tian,S.,Nie,J.,Jonsdottir,G.A.,Ruotti,V.,Stewart,R.,Slukvin,I.I.,andThomson,J.A.(2007)Inducedpluripotentstemcelllinesderivedfromhumansomaticcells.Science318:1917-1920.
Schopperle,W.M.,andDeWolf,W.C.(2007)TheTRA-1-60andTRA-1-81humanpluripotentstemcellmarkersareexpressedonpodocalyxininembryonalcarcinoma.StemCells25:723-730.
Chin,A.C.,Fong,W.J.,Goh,L.T.,Philp,R.,Oh,S.K.,andChoo,A.B.(2007)Identificationofproteinsfromfeederconditionedmediumthatsupporthumanembryonicstemcells.JBiotechnol.130:320-328.
Badcock,G.,Pigott,C.,Goepel,J.,andAndrews,P.W.(1999)ThehumanembryonalcarcinomamarkerantigenTRA-1-60isasialylatedkeratansulfateproteoglycan.CancerRes.59:4715-4719.
Andrews,P.W.,Banting,G.,Damjanov,I.,Arnaud,D.,andAvner,P.(1984)Threemonoclonalantibodiesdefiningdistinctdifferentiationantigensassociatedwithdifferenthighmolecularweightpolypeptidesonthesurfaceofhumanembryonalcarcinomacells.Hybridoma3:347-361.

AdditionalPublications

SridharA;OhlemacherSK;LangerKB;MeyerJS."RobustdifferentiationofmRNA-reprogrammedhumaninducedpluripotentstemcellstoardaretinallineage."StemCellTranslationalMedicine5:10(2016)
OhlemacherSK;SridharA;XiaoY;HochstetlerAE;SarfaraziM;CumminsTR;MeyerJS."Stepwisedifferentiationofretinalganglioncellsfromhumanpluripotentstemcellsenablesanalysisofglaucomatousneurodegeneration."StemCellsdoi:10.1002/stem.2356(2016)
PoleganovMA;EminliS;BeissertT;HerzS;MoonJ-I;GoldmannJ;BeyerA;HeckR;BurkhartI;RoldanDB;TureciO;YiK;HamiltonB;SahinU."Efficientreprogrammingofhumanfibroblastsandblood-derivedendothelialProgenitorcellsusingnonmodifiedRNAforreprogrammingandimmuneevasion."HumanGeneTherapy26:751(2015)
BriggsSF;DominguezAA;ChavezSL;ReijoPeraRA."XISTinhumanpreimplantationembryosandiPSCs."StemCells33:1771(2015)
WangJ;HuangV;YeL;BarcenaA;LinG;LueTF;LiL-C."IdentificationofsmallactivatingRNAsthatenhanceendogenousOCT4expressioninhumanmesenchymalstemcells."StemCellsDevelop24:345(2015)
HaraguchiY;MatsuuraK;ShimizuT;YamatoM;OkanoT."SimplesUSPensionculturesystemofhumaniPScellsmaintiantingthepluripotencyforcardiaccellsheetengineering."JTissueEngRegenMedicine9:1363(2015)
RajasinghS;ThangavelJ;CzirokA;SamantaS."GenerationoffunctionalcardiomyocytesfromefficientlygeneratedhumaniPSCsandanovelmethodformeasuringcontractility."PLoSone(2015)
TanH-K;TohC-XDlMaD;YangB;LiuTM;LuJ;WongC-W;TanT-K;LiH;SYnC;TanE-L;LimB;LimY-P;CookSA;LohY-H."Humanfinger-prickinducedpluripotentstemcellsfacilitatethedevelopmentofstemcellbanking."StemCellsTransMedicine3:586(2014)

品牌介绍

Stemgent mRNA体细胞重编程系统

产品特点

1.快速 Fast

Stemgent® MicroRNA-Enhanced mRNA Reprogramming System只需2周即可将靶细胞重编程为iPS细胞，与仙台病毒（Sendai Virus）、非整合型DNA载体（Episomal DNA Vectors）等传统iPS重编程方法相比，缩短实验周期超过50%以上（Figure. 1）。

Figure 1. Stemgent® mRNA重编程系统、仙台病毒依赖的重编程系统以及游离型DNA载体依赖的重编程系统重编程时程比较。

简便 Easy

与病毒、DNA载体依赖的iPS重编程手段不同，使用Stemgent® MicroRNA-Enhanced mRNA Reprogramming System对靶细胞进行重编程，生成的iPS细胞无需进行复杂耗时的下游筛选程序，只需简简单单6个步骤，即可轻松构建iPS细胞系。

	Description	Day
Step 1	Material Preparation	Prior to starting
Step 2	Plate Cells	0
Step 3	Transfect Cells	1 to 12
Step 4	Identify Cells	13-14
Step 5	Pick and Passage iPS Cell Colonies	15-16
Step 6	Maintain iPS Cell Cultures	16+

注：因所用细胞类型及实验条件不同，上述时间轴可能略有不同，仅供参考。

Figure 2. Stemgent® MicroRNA-Enhanced mRNA Reprogramming System重编程过程时间表、显微镜下观察到的重编程过程中靶细胞形态变化。第12天，形成的iPS克隆表达多能型Marker TRA-1-81。

高效 Efficient

病毒、DNA载体等依赖的iPS重编程技术，其重编程效率介于0.00001%到1%之间不等，而Stemgent® MicroRNA-Enhanced mRNA Reprogramming System的重编程效率远远大于1%，极大地提高了iPS克隆的产出率。

表1. 不同类型iPS重编程手段效率比较

Reprogramming Method	Efficiency	Integrating	Screening
RNA	>1%	No	No
仙台病毒（Sendai virus）	0.01-1%	No	Yes
DNA载体（Episomal/Minicircle）	0.00%	Possible	Yes
慢病毒（Lentivirus）	0.001-0.01%	Yes	Yes
腺病毒（Adenovirus）	0.0001-0.001%	Possible	Yes
Protein	0.00%	No	No

安全 Safe

某些iPS研究领域，例如iPS临床研究、治疗应用等，对iPS细胞的安全性提出了极高的要求。使用Stemgent® MicroRNA-Enhanced mRNA Reprogramming System重编程靶细胞，无需担心构建的iPS细胞系可能含有病毒载体残留，亦无需担心无关的基因整合进宿主基因组，是目前适用于临床研究及治疗的最理想选择。

而以仙台病毒（Sendai Virus）为载体的iPS重编程手段，其病毒基因组虽然不会整合进宿主染色体，仙台病毒本身也不具备复制能力，但是为了构建真正意义上的virus-free的iPS细胞系，通常需要经过一个10-20代、耗时费力的筛选过程，以确保最终得到的iPS细胞系无病毒载体残留。以慢病毒（Lentivirus）体的iPS重编程手段，病毒基因组能够永久整合进宿主基因组，会给后续的iPS细胞分析带来干扰。